RayKnowChina Research Map
Shortlist

ChangshaCentral South University (Xiangya)

Second Xiangya Hospital

中南大学湘雅二医院

Listed for 33 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Second Xiangya Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌25 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌6 papers led
  3. Hepatocellular carcinoma肝细胞癌55 papers led
  4. Stomach cancer胃癌32 papers led
  5. Retinoblastoma视网膜母细胞瘤1 paper led
  6. Chordoma脊索瘤2 papers led
  7. Osteosarcoma骨肉瘤42 papers led
  8. Gastrointestinal stromal tumour胃肠道间质瘤4 papers led
  9. Neuroblastoma神经母细胞瘤5 papers led
  10. Ewing sarcoma尤文肉瘤1 paper led
  11. Multiple myeloma多发性骨髓瘤14 papers led
  12. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病3 papers led
  13. Aplastic anaemia再生障碍性贫血6 papers led
  14. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症2 papers led
  15. Beta thalassaemiaβ 地中海贫血2 papers led
  16. Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征1 paper led
  17. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  18. Fanconi anaemia范可尼贫血5 papers led
  19. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病7 papers led
  20. IgG4-related diseaseIgG4相关性疾病1 paper led
  21. Myasthenia gravis重症肌无力6 papers led
  22. Wilson disease肝豆状核变性(Wilson 病)7 papers led
  23. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎3 papers led
  24. Takayasu arteritis大动脉炎5 papers led
  25. Idiopathic pulmonary fibrosis特发性肺纤维化18 papers led
  26. Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病3 papers led
  27. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  28. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  29. Behçet disease白塞病1 paper led
  30. IgA nephropathyIgA 肾病14 papers led
  31. Osteogenesis imperfecta成骨不全症0 papers led
  32. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
  33. Familial adenomatous polyposis家族性腺瘤性息肉病1 paper led

Not listed for: Hepatoblastoma, Haemophilia A, Moyamoya disease, Biliary atresia, Hepatic echinococcosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 25 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 1.1%.

Papers led
25
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 4420222023: 3320232024: 8820242025: 992025

5 hospitals in Changsha for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRadiotherapy techniqueImaging & AIImmunotherapy
Departments in papersPathology / laboratory medicineMedical oncologyENT / head & neck surgeryNephrology

Over half of these papers are lab or animal studies.

Papers it led25
  1. A11 Peptide Enhances Radiosensitivity by Degrading EphA2 in Nasopharyngeal Carcinoma.2026Cancer scienceFree full text
  2. Programmed cell death in nasopharyngeal carcinoma: Mechanisms and therapeutic targets.2025Biochimica et biophysica acta. Reviews on cancer
  3. Targeting EGFR-binding protein SLC7A11 enhancing antitumor immunity of T cells via inducing MHC-I antigen presentation in nasopharyngeal carcinoma.2025Cell death & diseaseFree full text
  4. The Combined Treatment of 4EGl-1 and MK-2206 Inhibits Nasopharyngeal Carcinoma Progress by Inducing Autophagy.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  5. SSTR2 exhibits a positive correlation with PD-L1 and predicts poor prognosis in nasopharyngeal carcinoma.2025International immunopharmacology
  6. Ferroptosis inhibition via the ROS-GPX4 axis drives microplastic-induced malignant progression of nasopharyngeal carcinoma.2025Journal of translational medicineFree full text
  7. Unveiling immune resistance mechanisms in nasopharyngeal carcinoma and emerging targets for antitumor immune response: tertiary lymphoid structures.2025Journal of translational medicineFree full text
  8. Nomograms Based on Blood-Based Biomarkers for Predicting Prognosis in Locally Advanced Nasopharyngeal Carcinoma Patients.2025Mediators of inflammationFree full text
  9. Deep learning based analysis of G3BP1 protein expression to predict the prognosis of nasopharyngeal carcinoma.2025PloS oneFree full text
  10. Nasogastric tube nutrition support enhances chemoradiotherapy compliance and alleviates mucosal reactions in nasopharyngeal carcinoma: a 856-case retrospective cohort study.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  11. Tumor-associated macrophage-derived itaconic acid contributes to nasopharyngeal carcinoma progression by promoting immune escape via TET2.2024Cell communication and signaling : CCSFree full text
  12. Predicting the overall survival and progression-free survival of nasopharyngeal carcinoma patients based on hemoglobin, albumin, and globulin ratio and classical clinicopathological parameters.2024Head & neck
  13. Suppression of the SLC7A11/glutathione axis causes ferroptosis and apoptosis and alters the mitogen-activated protein kinase pathway in nasopharyngeal carcinoma.2024International journal of biological macromolecules
  14. G3BP1 Interact with JAK2 mRNA to Promote the Malignant Progression of Nasopharyngeal Carcinoma via Activating JAK2/STAT3 Signaling Pathway.2024International journal of biological sciencesFree full text
  15. SSTR2 positively associates with EGFR and predicts poor prognosis in nasopharyngeal carcinoma.2024Journal of clinical pathologyFree full text
  16. Comparative Proteomics Identified EXOSC1 as a Target Protein of Anticancer Peptide LVTX-8 in Nasopharyngeal Carcinoma Cells.2024Journal of proteome research
  17. LINC00313 suppresses autophagy and promotes stemness of nasopharyngeal carcinoma cells through PTBP1/STIM1 axis.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  18. Nomograms based on the lymphocyte-albumin-neutrophil ratio (LANR) for predicting the prognosis of nasopharyngeal carcinoma patients after definitive radiotherapy.2024Scientific reportsFree full text
  19. Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China.2023BMJ openFree full text
  20. CircLASP1 silence strengthens the therapeutic effects of MK-2206 on nasopharyngeal cancer through upregulating miR-625.2023Cancer scienceFree full text
  21. Prognostic value of the fibrinogen albumin ratio index (FARI) in nasopharyngeal carcinoma patients undergoing radiotherapy.2023Scientific reportsFree full text
  22. Circ_0000523 regulates miR-1184/COL1A1/PI3K/Akt pathway to promote nasopharyngeal carcinoma progression.2022Apoptosis : an international journal on programmed cell death
  23. Emerging roles of lncRNA in Nasopharyngeal Carcinoma and therapeutic opportunities.2022International journal of biological sciencesFree full text
  24. Nedaplatin-based chemotherapy or cisplatin-based chemotherapy combined with intensity-modulated radiotherapy achieve similar efficacy for stage II-IVa nasopharyngeal carcinoma patients.2022Scientific reportsFree full text
  25. YB1 associates with oncogenetic roles and poor prognosis in nasopharyngeal carcinoma.2022Scientific reportsFree full text
Chinese-language papers (not in the count)1
  1. Prognostic value of pretreatment peripheral blood hemoglobin×lymphocyte/monocyte ratio in patients with nasopharyngeal carcinoma.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
All its trials on ClinicalTrials.gov, any status4
  1. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04974398Study sitePhase 3Start 2021-08
  2. Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid TumorsCompletedNCT04215978Study sitePhase 1Start 2020-01
  3. The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal CancerCompletedNCT03581786Study sitePhase 3Start 2018-10
  4. A Trial of Endostar in Patients With Carcinoma of the Head and NeckStatus unknownNCT02902432Study sitePhase 2Start 2016-06
More papers found outside PubMed (not counted)30
  1. 669MO Long term overall survival follow-up of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma2025Annals of Oncologyarticle
  2. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Researchconference-abstract
  3. CircARHGAP12 suppresses cisplatin-induced alkaliptosis in nasopharyngeal carcinoma through G3BP1-mediated upregulation of CA9 in an RNA G-quadruplex-dependent manner2025Research Squarepreprint
  4. Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.2025Journal of Clinical Oncologyconference-abstract
  5. Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC).2024Journal of Clinical Oncologyconference-abstract
  6. Prognostic analysis of nimotuzumab combined with concurrent chemoradiotherapy in locally advanced cervical cancer: A multicenter real-world study.2024Journal of Clinical Oncologyconference-abstract
  7. RETRACTED: METTL14 Promotes Lipid Metabolism Reprogramming and Sustains Nasopharyngeal Carcinoma Progression via Enhancing m6A Modification of ANKRD22 mRNA2024Research Squarepreprint
  8. Antitumor regimens with gemcitabine are safe for tumor patients with COVID-19.2023Journal of Clinical Oncologyconference-abstract
  9. Data from Epstein–Barr Virus–Encoded Circular RNA CircBART2.2 Promotes Immune Escape of Nasopharyngeal Carcinoma by Regulating PD-L12023Venue not listedother
  10. Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2023Journal of Clinical Oncologyconference-abstract
  11. Impact of radiotherapy for nasopharyngeal carcinoma on carotid stenosis risk: a meta-analysis2023Figsharedataset
  12. Abstract CT226: Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal ca2022Cancer Researchconference-abstract
  13. Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma2022Figsharedataset
  14. Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  15. Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  16. Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  17. Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  18. Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  19. Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  20. Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  21. Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  22. Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  23. Fabrication of metformin and survivin siRNA encapsulated into polyethyleneimine-altered silk fibroin nanoparticles for the treatment of nasopharyngeal carcinoma2022Process Biochemistryarticle
  24. 436 A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy2021Journal for ImmunoTherapy of Cancerconference-abstract
  25. Additional file 1 of Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO22021Figsharedataset
  26. Additional file 2 of Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO22021Figsharedataset
  27. Combination of CD47 Expression and SIRI as a Prognostic Factor in Nasopharyngeal Carcinoma Patients2021Research Squarepreprint
  28. Elevated transcriptional pausing of RNA polymerase II underlies acquired resistance to radiotherapy2021bioRxiv (Cold Spring Harbor Laboratory)preprint
  29. JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2021Journal of Clinical Oncologyconference-abstract
  30. [Retracted] MicroRNA‑19a promotes nasopharyngeal carcinoma by targeting transforming growth factor β receptor 22021Experimental and Therapeutic Medicinearticle

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 6 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 1120232024: 0020242025: 002025

3 hospitals in Changsha for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImmunotherapyMolecular markers & genomics
Departments in papersGastroenterology / hepatology

Over half of these papers are lab or animal studies.

Papers it led6
  1. Human umbilical cord mesenchymal stem cell-derived extracellular vesicles carrying miR-655-3p inhibit the development of esophageal cancer by regulating the expression of HIF-1α via a LMO4/HDAC2-dependent mechanism.2023Cell biology and toxicology
  2. Effects and mechanisms of FBXO31 on Taxol chemoresistance in esophageal squamous cell carcinoma.2022Biochemical and biophysical research communications
  3. Cost-effectiveness analysis of pembrolizumab vs. chemotherapy as second-line treatment for advanced esophageal carcinoma in the United States.2022Frontiers in public healthFree full text
  4. Network analysis of genes associated with esophageal squamous cell carcinoma progression.2022Journal of investigative medicine : the official publication of the American Federation for Clinical Research
  5. FBX4 mediates rapid cyclin D1 proteolysis upon DNA damage in immortalized esophageal epithelial cells.2021Biochemical and biophysical research communications
  6. Reduced LINC00551 expression promotes proliferation and invasion of esophageal squamous cancer by increase in HSP27 phosphorylation.2021Journal of cellular physiology
All its trials on ClinicalTrials.gov, any status1
  1. Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)CompletedNCT02649361Study sitePhase 2Start 2016-01
More papers found outside PubMed (not counted)5
  1. 470eP Multimodal imaging–clinical modeling to predict pathologic response after neoadjuvant chemoimmunotherapy for resectable ESCC2025Annals of Oncologyarticle
  2. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  3. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  4. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  5. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 55 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
55
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 8820212022: 9920222023: 151520232024: 111120242025: 11112025

6 hospitals in Changsha for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07209813

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Nanchang, Nanjing, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisLocal treatment (ablation, TACE, HAIC)Immunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicinePathology / laboratory medicineGastroenterology / hepatology
Papers it led55
  1. Identification of Bruceine A as a novel HSP90AB1 inhibitor for suppressing hepatocellular carcinoma growth.2026Journal of advanced researchFree full text
  2. Comparison of Diagnostic Accuracies of Radiomics and Non-radiomics Model for Preoperative Prediction of Macrotrabecular-Massive Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.2025Academic radiology
  3. High Fibroblast Activation Protein Expression in Hepatocellular Carcinoma: CT Imaging Features and Histological Characteristics.2025Academic radiology
  4. The Role of ROS and Its Sources in Tumorigenesis: Friend or Foe?2025Advanced biology
  5. ZDHHC12 Palmitoylates HDAC8 to Promote the Progression of Hepatocellular Carcinoma Associated with a Diet High in Saturated Fatty Acids.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  6. SLC1A4 Promotes Malignant Transformation of Hepatocellular Carcinoma by Activating the AKT Signaling.2025Analytical cellular pathology (Amsterdam)Free full text
  7. Synthesis and biological evaluation of 4-((3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)quinoline derivatives as novel potential transforming growth factor-β type 1 receptor inhibitors for hepatocellular carcinoma.2025Bioorganic chemistry
  8. Targeting MCM10 disrupts cancer stemness and counteracts sorafenib resistance in hepatocellular carcinoma.2025Cancer gene therapyFree full text
  9. RAB40C recruiting TRIM21 facilitates the progression of hepatocellular carcinoma by stabilizing EGFR.2025Cell communication and signaling : CCSFree full text
  10. The outcomes and mechanisms of chronic hepatitis B complicated by metabolic dysfunction-associated steatotic liver disease.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  11. Comparison of Atezolizumab plus Aevacizumab and Atezolizumab plus Aabozantinib for advanced hepatocellular carcinoma: A cost-effectiveness analysis.2025PloS oneFree full text
  12. Skeletal muscle index/systemic immune-inflammation index (SMI/SII) ratio predicts prognosis in patients with hepatocellular carcinoma.2025World journal of surgical oncologyFree full text
  13. CD36-mediated accumulation of MDSCs exerts abscopal immunosuppressive responses in hepatocellular carcinoma after insufficient microwave ablation.2024Biochimica et biophysica acta. Molecular basis of disease
  14. TRIM21 is critical in regulating hepatocellular carcinoma growth and response to therapy by altering the MST1/YAP pathway.2024Cancer scienceFree full text
  15. Genomic and immune landscape in hepatocellular carcinoma: Implications for personalized therapeutics.2024Environmental toxicology
  16. METTL5 enhances the mRNA stability of TPRKB through m6A modification to facilitate the aggressive phenotypes of hepatocellular carcinoma cell.2024Experimental cell research
  17. Identification and validation of immune-related gene signature models for predicting prognosis and immunotherapy response in hepatocellular carcinoma.2024Frontiers in immunologyFree full text
  18. Letter to the Editor: Intratumor fibrotic HCC, a subtype matching the Hoshida S1 subclass?2024Hepatology (Baltimore, Md.)
  19. A multi-omic analysis reveals that Gamabufotalin exerts anti-hepatocellular carcinoma effects by regulating amino acid metabolism through targeting STAMBPL1.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  20. Identification of the Roles of Coagulation-related Signature and its Key Factor RABIF in Hepatoma Cell Malignancy.2024Recent patents on anti-cancer drug discovery
  21. Subcutaneous adipose tissue/neutrophil-to-lymphocyte ratio is a potential biomarker in patients with hepatocellular carcinoma undergoing liver resection.2024Science progressFree full text
  22. Circular RNA DNAH14 molecular mechanism in an experimental model of hepatocellular carcinoma treated with Cobalt chloride to mimic the hypoxia-like response of transcatheter arterial chemoembolization.2024Scientific reportsFree full text
  23. Robotic anatomical resection for hepatocellular carcinoma located within segment 7 using the Glissonean approach.2024Updates in surgery
  24. Letter: repeat hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma in ideal candidates - authors' reply.2023Alimentary pharmacology & therapeutics
  25. Editorial: is microwave ablation an alternative to liver resection for hepatocellular carcinoma? Authors' reply.2023Alimentary pharmacology & therapeutics
  26. An Integrated Liver Function, Systemic Inflammation, and Tumor Characteristic Score Predicts Prognosis in Hepatocellular Carcinoma After Curative Resection.2023Annals of surgical oncology
  27. ASO Author Reflections: The FIBA Score-A Novel Scoring System to Predict Outcomes in Hepatocellular Carcinoma After Surgical Resection or Transarterial Chemoembolization.2023Annals of surgical oncologyFree full text
  28. Mechanism underlying the effect of Pulsatilla decoction in hepatocellular carcinoma treatment: a network pharmacology and in vitro analysis.2023BMC complementary medicine and therapiesFree full text
  29. Estimated projection of incidence and mortality of alcohol-related liver disease in China from 2022 to 2040: a modeling study.2023BMC medicineFree full text
  30. TRPM8 promotes hepatocellular carcinoma progression by inducing SNORA55 mediated nuclear-mitochondrial communication.2023Cancer gene therapy
  31. SLC12A5 promotes hepatocellular carcinoma growth and ferroptosis resistance by inducing ER stress and cystine transport changes.2023Cancer medicineFree full text
  32. Development and investigation of metabolism-associated risk assessment models for patients with viral hepatitis.2023Frontiers in cellular and infection microbiologyFree full text
  33. Multi-omics analysis reveals the involvement of origin recognition complex subunit 6 in tumor immune regulation and malignant progression.2023Frontiers in immunologyFree full text
  34. Kinesin family member 11 promotes progression of hepatocellular carcinoma via the OCT4 pathway.2023Functional & integrative genomics
  35. Association between antihypertensive drugs and hepatocellular carcinoma: A trans-ancestry and drug-target Mendelian randomization study.2023Liver international : official journal of the International Association for the Study of the Liver
  36. Upregulation of CSNK1A1 induced by ITGB5 confers to hepatocellular carcinoma resistance to sorafenib in vivo by disrupting the EPS15/EGFR complex.2023Pharmacological research
  37. First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.2023PloS oneFree full text
  38. Identifying Proliferative Hepatocellular Carcinoma at Pretreatment CT: Implications for Therapeutic Outcomes after Transarterial Chemoembolization.2023Radiology
  39. Combined transarterial iodized oil injection and computed tomography-guided thermal ablation for hepatocellular carcinoma: utility of the iodized oil retention pattern.2022Abdominal radiology (New York)Free full text
  40. Liver resection versus microwave ablation for hepatocellular carcinoma in ideal candidates for ablation per Barcelona Clinic Liver Cancer staging: a propensity score matching and inverse probability of treatment weighting analysis.2022Alimentary pharmacology & therapeutics
  41. Cell-free DNA methylation markers for differential diagnosis of hepatocellular carcinoma.2022BMC medicineFree full text
  42. DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma.2022Cancer lettersFree full text
  43. A novel DNA methylation-driver gene signature for long-term survival prediction of hepatitis-positive hepatocellular carcinoma patients.2022Cancer medicineFree full text
  44. S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway.2022Cell reports
  45. Identification of the Immune Subtype of Hepatocellular Carcinoma for the Prediction of Disease-Free Survival Time and Prevention of Recurrence by Integrated Analysis of Bulk- and Single-Cell RNA Sequencing Data.2022Frontiers in immunologyFree full text
  46. A Risk Model Developed Based on Necroptosis Predicts Overall Survival for Hepatocellular Carcinoma and Identification of Possible Therapeutic Drugs.2022Frontiers in immunologyFree full text
  47. Identification of two immune-related risk score signatures through integrated analysis of multi-omics data in hepatocellular carcinoma.2022Gene
  48. A predictive model of incomplete response after transarterial chemoembolization for early or intermediate stage of hepatocellular carcinoma: consideration of hepatic angiographic and cross-sectional imaging.2021Abdominal radiology (New York)
  49. Membrane protein-chimeric liposome-mediated delivery of triptolide for targeted hepatocellular carcinoma therapy.2021Drug deliveryFree full text
  50. Sintilimab plus sorafenib: a novel regimen for hepatocellular carcinoma.2021Immunotherapy
  51. The roles and mechanisms of hypoxia in liver fibrosis.2021Journal of translational medicineFree full text
  52. Integrated Liver Inflammatory Score Predicts the Therapeutic Outcome of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization.2021Journal of vascular and interventional radiology : JVIR
  53. Intra-platelet serotonin and YAP contributed to poor prognosis of hepatocellular carcinoma.2021Life sciences
  54. Prognostic value of the ALBI grade among patients with single hepatocellular carcinoma without macrovascular invasion.2021MedicineFree full text
  55. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma.2021TheranosticsFree full text
Chinese-language papers (not in the count)4
  1. Research progress in cuproptosis in liver cancer.2023Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  2. Role of miR-5010-3p in predicting the prognosis of hepatocellular carcinoma.2023Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  3. Regulatory effect of PINK1/Parkin axis on mitophagy in isoniazide-induced hepatocellular injury.2022Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  4. Mn-SOD alleviates methotrexate-related hepatocellular injury via GSK-3β affecting anti-oxidative stress of HO-1 and Drp1.2022Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
All its trials on ClinicalTrials.gov, any status1
  1. GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07209813Study sitePhase 2Start 2025-11

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 32 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
32
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 9920212022: 7720222023: 6620232024: 6620242025: 332025

4 hospitals in Changsha for stomach cancer218 hospitals in China for stomach cancer

No open trial on stomach cancer lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesEarly detection & endoscopyImaging & AIPeritoneal spread & advanced disease
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyMedical oncology
Papers it led32
  1. FTO Upregulates GLG1 Expression via m6A Methylation Modification to Facilitate Gastric Cancer Cell Migration and Invasion.2026Journal of gastroenterology and hepatology
  2. Association between metabolic syndrome and prognosis in elderly gastric cancer patients.2025Geriatric nursing (New York, N.Y.)
  3. Brucine Inhibits Gastric Cancer via Activation of Ferroptosis Through Regulating the NF-κB Signaling Pathway.2025Journal of biochemical and molecular toxicology
  4. Endoscopic ultrasound-guided bite-on-bite biopsy and endoscopic ultrasound-guided fine-needle aspiration in the diagnosis of gastric tumors with negative malignant endoscopy biopsies: a retrospective cohort study.2025Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  5. Silencing immune-infiltrating biomarker CCDC80 inhibits malignant characterization and tumor formation in gastric cancer.2024BMC cancerFree full text
  6. Circ_PABPC1 promotes the malignancy of gastric cancer through interacting with ILK to activate NF-κB pathway.2024Experimental cell research
  7. Development of a urine-based metabolomics approach for multi-cancer screening and tumor origin prediction.2024Frontiers in immunologyFree full text
  8. Exosomal miR-502-5p suppresses the progression of gastric cancer by repressing angiogenesis through the Wnt/β-catenin pathway.2024Irish journal of medical science
  9. Personalizing age of gastric cancer screening based on comorbidity in China: Model estimates of benefits, affordability and cost-effectiveness optimization.2024Preventive medicine
  10. Lesion size affects the risk of technical difficulty in gastric endoscopic submucosal dissection.2024Scientific reportsFree full text
  11. Explore the active ingredients and potential mechanisms of JianPi QingRe HuaYu Methods in the treatment of gastric inflammation-cancer transformation by network pharmacology and experimental validation.2023BMC complementary medicine and therapiesFree full text
  12. SMC1A facilitates gastric cancer cell proliferation, migration, and invasion via promoting SNAIL activated EMT.2023BMC gastroenterologyFree full text
  13. The characteristics and clinical relevance of tumor fusion burden in non-EBV (+) gastric cancer with MSS.2023BMC gastroenterologyFree full text
  14. Utilizing circulating tumour DNA as a prognostic predictor of gastric cancer: a meta-analysis.2023Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  15. Circular RNA circPOFUT1 enhances malignant phenotypes and autophagy-associated chemoresistance via sequestrating miR-488-3p to activate the PLAG1-ATG12 axis in gastric cancer.2023Cell death & diseaseFree full text
  16. AGAP2-AS1 promotes the assembly of m6A methyltransferases and activation of the IL6/STAT3 pathway by binding with WTAP in the carcinogenesis of gastric cancer.2023FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  17. Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma.2022BMJ openFree full text
  18. Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China: A modeling study.2022Frontiers in public healthFree full text
  19. Long non-coding RNA SNHG1/microRNA-195-5p/Yes-associated protein axis affects the proliferation and metastasis of gastric cancer via the Hippo signaling pathway.2022Functional & integrative genomics
  20. Upregulated Solute Carrier SLC39A1 Promotes Gastric Cancer Proliferation and Indicates Unfavorable Prognosis.2022Genetics researchFree full text
  21. LncRNA NR2F2-AS1 functions as a tumor suppressor in gastric cancer through targeting miR-320b/PDCD4 pathway.2022Histology and histopathology
  22. Kinesin family member 2A links with advanced tumor stage, reduced chemosensitivity and worse prognosis in gastric cancer.2022Journal of clinical laboratory analysisFree full text
  23. Clinical Benefit and Cost Effectiveness of Risk-Stratified Gastric Cancer Screening Strategies in China: A Modeling Study.2022PharmacoEconomics
  24. STAM2 knockdown inhibits proliferation, migration, and invasion by affecting the JAK2/STAT3 signaling pathway in gastric cancer.2021Acta biochimica et biophysica Sinica
  25. Expression and prognosis analyses of BUB1, BUB1B and BUB3 in human sarcoma.2021AgingFree full text
  26. The prognostic value of circular RNA regulatory genes in competitive endogenous RNA network in gastric cancer.2021Cancer gene therapy
  27. LINC01133 hampers the development of gastric cancer through increasing somatostatin via binding to microRNA-576-5p.2021Epigenomics
  28. Genome Instability-Related miRNAs Predict Survival, Immune Landscape, and Immunotherapy Responses in Gastric Cancer.2021Journal of immunology researchFree full text
  29. Efficacy and safety of submucosal tunneling endoscopic resection for gastric submucosal tumors: a systematic review and meta-analysis.2021Revista espanola de enfermedades digestivas
  30. Factors that predict the technical difficulty during endoscopic full-thickness resection of a gastric submucosal tumor.2021Revista espanola de enfermedades digestivas
  31. Factors predicting technical difficulties during endoscopic submucosal excavation for gastric submucosal tumor.2021The Journal of international medical researchFree full text
  32. Value of HMGB1 expression for assessing gastric cancer severity: a systematic meta-analysis.2021The Journal of international medical researchFree full text
All its trials on ClinicalTrials.gov, any status6
  1. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  2. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  3. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  4. Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric CancerStatus unknownNCT03273920Study siteN/AStart 2017-09
  5. Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2Status unknownNCT02356276Study sitePhase 3Start 2015-05
  6. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

6 hospitals in Changsha for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology
Papers it led1
  1. Induction of autophagy-dependent ferroptosis to eliminate drug-tolerant human retinoblastoma cells.2022Cell death & disease
Earlier papers (2016–2020)2
  1. Case Report: Adult Retinoblastoma Progression in 19 Months.2020Optometry and vision science : official publication of the American Academy of Optometry
  2. MALAT1 modulates the autophagy of retinoblastoma cell through miR-124-mediated stx17 regulation.2018Journal of cellular biochemistry
All its trials on ClinicalTrials.gov, any status1
  1. A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of RetinoblastomaStatus unknownNCT04990271Study sitePhase 2Start 2021-07

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 2 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 1.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

6 hospitals in Changsha for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led2
  1. Letter: Tumor Growth Rate as a New Predictor of Progression-Free Survival After Chordoma Surgery.2022Neurosurgery
  2. Letter to the editor of radiotherapy and oncology regarding the article "Carbon ion radiotherapy for sacral chordoma: A retrospective nationwide multicentre study in Japan" by Demizu et al.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Earlier papers (2016–2020)19
  1. The Relationship Between Tumor-Stroma Ratio, the Immune Microenvironment, and Survival in Patients With Spinal Chordoma.2019Neurosurgery
  2. Clinicopathological and Prognostic Characteristics in Extra-Axial Chordomas: An Integrative Analysis of 86 Cases and Comparison With Axial Chordomas.2019Neurosurgery
  3. Clinical Impact of the Immune Microenvironment in Spinal Chordoma: Immunoscore as an Independent Favorable Prognostic Factor.2019Neurosurgery
  4. Clinicopathologic implications of CD8+/Foxp3+ ratio and miR-574-3p/PD-L1 axis in spinal chordoma patients.2018Cancer immunology, immunotherapy : CII
  5. Letter to the Editor. Brachyury as prognostic biomarker in chordoma.2018Journal of neurosurgery
  6. CDK4 expression in chordoma: A potential therapeutic target.2018Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  7. Analysis of prognostic factors for survival in patients with primary spinal chordoma using the SEER Registry from 1973 to 2014.2018Journal of orthopaedic surgery and research
  8. Letter: Cranial Chordoma: A New Preoperative Grading System.2018Neurosurgery
  9. Prognostic Factors in Clival Chordomas: An Integrated Analysis of 347 Patients.2018World neurosurgery
  10. Prognostic Factors in Skull Base Chordoma: A Systematic Literature Review and Meta-Analysis.2018World neurosurgery
  11. Expression of far upstream element-binding protein 1 correlates with c-Myc expression in sacral chordomas and is associated with tumor progression and poor prognosis.2017Biochemical and biophysical research communications
  12. Letter to the Editor concerning "Surgical treatment of sacral chordoma: survival and prognostic factors" by C. Ruosi et al. (Eur Spine J; 2015; 24(Suppl 7):S912-S917.2017European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  13. Letter to the Editor: Influence of age on survival outcomes in patients with spinal chordoma.2017Journal of neurosurgery. Spine
  14. Prognostic factors in spinal chordoma: An update of current systematic review and meta-analysis.2017Journal of surgical oncology
  15. Letter: Factors Predicting Recurrence after Resection of Clival Chordoma Using Variable Surgical Approaches and Radiation Modalities.2017Neurosurgery
  16. Prognostic Factors in Patients With Spinal Chordoma: An Integrative Analysis of 682 Patients.2017Neurosurgery
  17. Ki-67 Index as a Prognostic Marker in Chordomas: A Systematic Review of the Literature.2017World neurosurgery
  18. Prognostic Significance of Resection Degree in Skull Base Chordoma: A Systematic Review and Meta-Analysis.2017World neurosurgery
  19. Prognostic Biomarkers in Spinal Chordoma: A Systematic Review.2016Journal of neuropathology and experimental neurology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 42 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 1.9%.

Papers led
42
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 8820212022: 121220222023: 2220232024: 111120242025: 882025

14 hospitals in Changsha for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersENT / head & neck surgeryPathology / laboratory medicineMedical oncology

Over half of these papers are lab or animal studies.

Papers it led42
  1. Dual Targeting of m7G tRNA Modification and Histone Acetylation using Carrier-Free Nano-Epidrugs to Evoke Osteosarcoma Chemosensitization.2026Advanced materials (Deerfield Beach, Fla.)
  2. Targeting Mitochondrial Oxidative Stress by Calcium/Copper/Elesclomol Tri-Overloaded Nanocages for Osteosarcoma Immunotherapy via Immunogenic Cell Death.2025ACS nano
  3. Assembly of a biomimetic copper-based nanocomplex for alleviating hypoxia to enhance cuproptosis against osteosarcoma and lung metastasis.2025Acta biomaterialia
  4. A Dual Approach with Organoid and CRISPR Screening Reveals ERCC6 as a Determinant of Cisplatin Resistance in Osteosarcoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  5. RFWD3 Reprograms Nucleotide Metabolism Through PHGDH to Induce Chemoresistance In Osteosarcoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  6. Heterogeneity in Osteosarcoma Revealed by scRNA Sequencing: CLU+ Endothelial Cells as Key Players in Tumor Progression.2025Cancer science
  7. Ubiquitin-conjugating enzyme E2S (UBE2S) as a prognostic biomarker and regulator of tumorigenesis in osteosarcoma.2025International immunopharmacology
  8. Cooperative blockade of FLT3 and ALK synergistically suppresses growth of osteosarcoma.2025Oncogene
  9. PKMYT1 kinase ameliorates cisplatin sensitivity in osteosarcoma.2025Signal transduction and targeted therapy
  10. Endoprosthetic replacement with preservation of the epiphysis for proximal tibial reconstruction after osteosarcoma resection in children: a case report.2024BMC musculoskeletal disorders
  11. PRKDC Induces Chemoresistance in Osteosarcoma by Recruiting GDE2 to Stabilize GNAS and Activate AKT.2024Cancer research
  12. RNA modification-related EIF4G2 is an immunotherapy determinant in osteosarcoma: A single-cell sequencing analysis.2024Environmental toxicology
  13. SPP1 could be an immunological and prognostic biomarker: From pan-cancer comprehensive analysis to osteosarcoma validation.2024FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  14. Circulating immune cells and risk of osteosarcoma: a Mendelian randomization analysis.2024Frontiers in immunology
  15. The role of disulfidptosis-associated LncRNA-LINC01137 in Osteosarcoma Biology and its regulatory effects on macrophage polarization.2024Functional & integrative genomics
  16. RREB1 could act as an immunological and prognostic biomarker: From comprehensive analysis to osteosarcoma validation.2024International immunopharmacology
  17. Bibliometric analysis and visualisation of research hotspots and frontiers on omics in osteosarcoma.2024Journal of cancer research and clinical oncology
  18. Identification and Validation of a Novel PANoptosis-related Gene Signatured for Osteosarcoma as Prognostic Model.2024Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  19. Radiomics analysis in differentiating osteosarcoma and chondrosarcoma based on T2-weighted imaging and contrast-enhanced T1-weighted imaging.2024Scientific reports
  20. Machine learning survival prediction using tumor lipid metabolism genes for osteosarcoma.2024Scientific reports
  21. The Eph/Ephrin system in primary bone tumor and bone cancer pain.2023Aging
  22. The BRD4-SRPK2-SRSF2 signal modulates the splicing efficiency of ACSL3 pre-mRNA and influences erastin-induced ferroptosis in osteosarcoma cells.2023Cell death & disease
  23. Circ_0003732 promotes osteosarcoma progression through regulating miR-377-3p/CPEB1 axis and Wnt/β-catenin signaling pathway.2022Anti-cancer drugs
  24. Mir-34a: a regulatory hub with versatile functions that controls osteosarcoma networks.2022Cell cycle (Georgetown, Tex.)
  25. Intelligent Segmentation Medical Assistance System for MRI Images of Osteosarcoma in Developing Countries.2022Computational and mathematical methods in medicine
  26. A Residual Fusion Network for Osteosarcoma MRI Image Segmentation in Developing Countries.2022Computational intelligence and neuroscience
  27. Extraosseous Ewing Sarcoma of the Cervical Esophagus: Case Report and Literature Review.2022Ear, nose, & throat journal
  28. Knowledge atlas and emerging trends on ncRNAs of osteosarcoma: A bibliometric analysis.2022Frontiers in endocrinology
  29. Identification of cuproptosis-related lncRNA prognostic signature for osteosarcoma.2022Frontiers in endocrinology
  30. Molecular characterization of immunogenic cell death indicates prognosis and tumor microenvironment infiltration in osteosarcoma.2022Frontiers in immunology
  31. Effects of butein on human osteosarcoma cell proliferation, apoptosis, and autophagy through oxidative stress.2022Human & experimental toxicology
  32. Hybrid Cell Membrane-Functionalized Biomimetic Nanoparticles for Targeted Therapy of Osteosarcoma.2022International journal of nanomedicine
  33. The emerging role of pyroptosis in pediatric cancers: from mechanism to therapy.2022Journal of hematology & oncology
  34. MicroRNA-143 expression inhibits the growth and the invasion of osteosarcoma.2022Journal of orthopaedic surgery and research
  35. Identification of N6-methylandenosine related LncRNAs biomarkers associated with the overall survival of osteosarcoma.2021BMC cancer
  36. The relationship between the expression of Ki-67 and the prognosis of osteosarcoma.2021BMC cancer
  37. The value of lncRNAs as prognostic biomarkers on clinical outcomes in osteosarcoma: a meta-analysis.2021BMC cancer
  38. Identification of potential micro-messenger RNAs (miRNA-mRNA) interaction network of osteosarcoma.2021Bioengineered
  39. Noncoding RNAs in osteosarcoma: Implications for drug resistance.2021Cancer letters
  40. TRAIP modulates the IGFBP3/AKT pathway to enhance the invasion and proliferation of osteosarcoma by promoting KANK1 degradation.2021Cell death & disease
  41. Diagnostic and Prognostic Significance of Dysregulated Expression of Circular RNAs in Osteosarcoma.2021Expert review of molecular diagnostics
  42. Long Noncoding RNA HCG9 Promotes Osteosarcoma Progression through RAD51 by Acting as a ceRNA of miR-34b-3p.2021Mediators of inflammation
Chinese-language papers (not in the count)4
  1. Application and mechanisms of targeting BRD4 in osteosarcoma.2025Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  2. Downregulation of B4GALNT1 inhibits proliferation and metastasis of osteosarcoma cells.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  3. Curcumin inhibits the proliferation and migration of osteosarcoma by regulating the expression of super-enhancer-associated genes.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  4. [Bioinformatics Analysis on Key Genes and Immune Infiltration of Osteosarcoma].2022Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
Earlier papers (2016–2020)43
  1. LncRNA Sox2OT-V7 promotes doxorubicin-induced autophagy and chemoresistance in osteosarcoma via tumor-suppressive miR-142/miR-22.2020Aging
  2. The regulatory effect of has-circ-0001146/miR-26a-5p/MNAT1 network on the proliferation and invasion of osteosarcoma.2020Bioscience reports
  3. The prognostic role of CD133 expression in patients with osteosarcoma.2020Clinical and experimental medicine
  4. Role of exosomal miR‑21 in the tumor microenvironment and osteosarcoma tumorigenesis and progression (Review).2020International journal of oncology
  5. Emerging landscape of circular RNAs as biomarkers and pivotal regulators in osteosarcoma.2020Journal of cellular physiology
  6. The Role of Chemotherapy in Extraskeletal Osteosarcoma: A Propensity Score Analysis of the Surveillance Epidemiology and End Results (SEER) Database.2020Medical science monitor : international medical journal of experimental and clinical research
  7. Predictors and Survival of Patients with Osteosarcoma After Limb Salvage versus Amputation: A Population-Based Analysis with Propensity Score Matching.2020World journal of surgery
  8. Mechanism of the Notch signaling pathway in enhancing the efficacy of chemotherapy drugs in osteosarcoma.2020Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  9. Association between PTEN and clinical-pathological features of osteosarcoma.2019Bioscience reports
  10. The LncRNA LINC00963 facilitates osteosarcoma proliferation and invasion by suppressing miR-204-3p/FN1 axis.2019Cancer biology & therapy
  11. Characteristics and Prognostic Factors of Patients With Osteosarcoma Older Than 60 Years From the SEER Database.2019Cancer control : journal of the Moffitt Cancer Center
  12. miR-342-5p inhibits osteosarcoma cell growth, migration, invasion, and sensitivity to Doxorubicin through targeting Wnt7b.2019Cell cycle (Georgetown, Tex.)
  13. Long non-coding RNA ZFAS1 regulates NOB1 expression through interacting with miR-646 and promotes tumorigenesis in osteosarcoma.2019European review for medical and pharmacological sciences
  14. MicroRNA-29a suppresses the invasion and migration of osteosarcoma cells by regulating the SOCS1/NF-κB signalling pathway through negatively targeting DNMT3B.2019International journal of molecular medicine
  15. MAT1 facilitates the lung metastasis of osteosarcoma through upregulation of AKT1 expression.2019Life sciences
  16. A case report of primary osteosarcoma originating from kidney.2019Medicine
  17. Evaluation of the Efficacy of Pasteurized Autograft and Intramedullary Vascularized Fibular Transfer for Osteosarcoma of the Femoral Diaphysis.2019Orthopaedic surgery
  18. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.2019World neurosurgery
  19. [Suppression of miR-30a/HMGA2-mediated autophagy in osteosarcoma cells impacts chemotherapeutics-induced apoptosis].2019Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  20. miR-223/Hsp70/JNK/JUN/miR-223 feedback loop modulates the chemoresistance of osteosarcoma to cisplatin.2018Biochemical and biophysical research communications
  21. Targeting CD44 by CRISPR-Cas9 in Multi-Drug Resistant Osteosarcoma Cells.2018Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  22. CRISPR-Cas9-Mediated Silencing of CD44 in Human Highly Metastatic Osteosarcoma Cells.2018Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  23. Identification of potential crucial genes and construction of microRNA-mRNA negative regulatory networks in osteosarcoma.2018Hereditas
  24. SOX2OT variant 7 contributes to the synergistic interaction between EGCG and Doxorubicin to kill osteosarcoma via autophagy and stemness inhibition.2018Journal of experimental & clinical cancer research : CR
  25. The long noncoding RNA cancer susceptibility candidate 2 inhibits tumor progression in osteosarcoma.2018Molecular medicine reports
  26. The potential combinational effect of miR-34a with celecoxib in osteosarcoma.2017Anti-cancer drugs
  27. MALAT1 promotes osteosarcoma development by regulation of HMGB1 via miR-142-3p and miR-129-5p.2017Cell cycle (Georgetown, Tex.)
  28. Application of Long Noncoding RNAs in Osteosarcoma: Biomarkers and Therapeutic Targets.2017Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  29. Actin-like protein 6A is a novel prognostic indicator promoting invasion and metastasis in osteosarcoma.2017Oncology reports
  30. Pasteurized autograft reconstruction after resection of periacetabular malignant bone tumours.2017World journal of surgical oncology
  31. Krüppel-like factor 4 promotes high-mobility group box 1-induced chemotherapy resistance in osteosarcoma cells.2016Cancer science
  32. SerpinE2 promotes multiple cell proliferation and drug resistance in osteosarcoma.2016Molecular medicine reports
  33. Protein inhibitor of activated STAT xα depresses cyclin D and cyclin D kinase, and contributes to the inhibition of osteosarcoma cell progression.2016Molecular medicine reports
  34. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.2016Oncotarget
  35. Low expression of miR-381 is a favorite prognosis factor and enhances the chemosensitivity of osteosarcoma.2016Oncotarget
  36. mTOR: An attractive therapeutic target for osteosarcoma?2016Oncotarget
  37. Hypoxia-inducible factor-1 expression predicts osteosarcoma patients' survival: a meta-analysis.2016The International journal of biological markers
  38. miR-421 is a diagnostic and prognostic marker in patients with osteosarcoma.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  39. Green tea polyphenol EGCG suppresses osteosarcoma cell growth through upregulating miR-1.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  40. Total femoral reconstruction with custom prosthesis for osteosarcoma.2016World journal of surgical oncology
  41. Image and pathological features of Ewing's sarcoma in the oral and maxillofacial region.2016Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  42. [Efficacy of reconstruction with modular endoprosthesis after resection of periacetabular malignant tumors].2016Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  43. [miR-181a promotes the proliferation and metastasis of osteosarcoma cells by targeting RASSF1A].2016Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 4 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.8%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 2220242025: 112025

3 hospitals in Changsha for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatologyRadiology / nuclear medicineMedical oncologySurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 5 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 3320222023: 1120232024: 0020242025: 002025

8 hospitals in Changsha for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurologyNeurosurgery

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

3 hospitals in Changsha for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersENT / head & neck surgery
Papers it led1
  1. Extraosseous Ewing Sarcoma of the Cervical Esophagus: Case Report and Literature Review.2022Ear, nose, & throat journal
Earlier papers (2016–2020)3
  1. Pasteurized autograft reconstruction after resection of periacetabular malignant bone tumours.2017World journal of surgical oncology
  2. Image and pathological features of Ewing's sarcoma in the oral and maxillofacial region.2016Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  3. [Efficacy of reconstruction with modular endoprosthesis after resection of periacetabular malignant tumors].2016Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 14 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.8%.

Papers led
14
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 3320212022: 2220222023: 3320232024: 3320242025: 222025

4 hospitals in Changsha for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDrug combinationsDiagnosis, MRD & riskStem cell transplant
Departments in papersNeurology

Over half of these papers are lab or animal studies.

Papers it led14
  1. IRF4 (MUM1) in B-cell malignancies: molecular mechanisms, biological functions, and clinical implications.2026Pathology
  2. The function and mechanism of clinical trial agent CPI-613 in multiple myeloma.2025Biochemical pharmacology
  3. Enhancing staging in multiple myeloma using an m6A regulatory gene-pairing model.2025Clinical and experimental medicineFree full text
  4. Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems.2024Blood cancer journalFree full text
  5. Single-cell sequencing analysis of multiple myeloma heterogeneity and identification of new theranostic targets.2024Cell death & diseaseFree full text
  6. Enhancing multiple myeloma staging: a novel cell death risk model approach.2024Clinical and experimental medicineFree full text
  7. Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS.2023Blood advancesFree full text
  8. Tumor Lysis Syndrome Associated with Monoclonal Antibodies in Patients with Multiple Myeloma: A Pharmacovigilance Study Based on the FAERS Database.2023Clinical pharmacology and therapeutics
  9. LINC00461 Knockdown Enhances the Effect of Ixazomib in Multiple Myeloma Cells.2023Current cancer drug targets
  10. CC1007, a small molecular compound, suppresses multiple myeloma via upregulation of Nur77.2022Bioorganic chemistry
  11. Polyphyllin VII, a novel moesin inhibitor, suppresses cell growth and overcomes bortezomib resistance in multiple myeloma.2022Cancer letters
  12. Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma.2021Advances in therapy
  13. Albendazole inhibits NF-κB signaling pathway to overcome tumor stemness and bortezomib resistance in multiple myeloma.2021Cancer letters
  14. First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness Analysis.2021Clinical therapeutics
Chinese-language papers (not in the count)1
  1. Diagnosis and treatment of multiple myeloma in Hunan Province.2022Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
All its trials on ClinicalTrials.gov, any status4
  1. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  2. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  3. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Study sitePhase 3Start 2024-01
  4. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentActive, not recruitingNCT05455320Study sitePhase 3Start 2022-10

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 3 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 1.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 222025

4 hospitals in Changsha for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
    Phase
    Phase 2
    Started
    2022-01
    Registry
    NCT05334823

    Age 3 years to 21 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shenzhen, Suzhou, Tianjin, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPhiladelphia chromosome & geneticsCAR-T & cell therapy

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 6 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 1.5%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 3320222023: 2220232024: 1120242025: 002025

2 hospitals in Changsha for aplastic anaemia63 hospitals in China for aplastic anaemia

No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImmunosuppressive treatmentThrombopoietin drugsChildren
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 2 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

4 hospitals in Changsha for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesStem cell transplantEBV & infection triggersChildren
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 2 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.6%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

5 hospitals in Changsha for beta thalassaemia157 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征

Led 1 of the 27 English-language PubMed papers on atypical haemolytic uraemic syndrome with an author in mainland China, 2021–2025: 3.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

2 hospitals in Changsha for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome

No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

5 hospitals in Changsha for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led 5 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 7.3%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 3320222023: 2220232024: 0020242025: 002025

2 hospitals in Changsha for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 7 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 1.4%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 1120232024: 1120242025: 002025

2 hospitals in Changsha for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06413654

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAntibodies & diagnosisImagingPregnancy, children, older adults
Departments in papersNeurologyRadiology / nuclear medicinePediatricsOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 1 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Changsha for IgG4-related disease46 hospitals in China for IgG4-related disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07222553

    Age 2 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Changsha

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesHead, eye socket & salivary glandsKidney, retroperitoneum & vessels
Departments in papersOphthalmology / neuro-ophthalmologyPathology / laboratory medicine
Papers it led1
  1. IgG4-related ophthalmic disease masquerading as ciliary body tumors and scleritis in both eyes: a case report.2023BMC ophthalmologyFree full text
Chinese-language papers (not in the count)2
  1. Clinical characteristics of IgG4-related disease with lung involvement in 14 patients.2023Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  2. Lung adenocarcinoma misdiagnosed as IgG4-related lung disease: A case report and literature review.2021Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
All its trials on ClinicalTrials.gov, any status1
  1. Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RDNot yet recruitingNCT07222553Study sitePhase 2Start 2026-10
More papers found outside PubMed (not counted)1
  1. A Rare Case of IgG4-related Disease Manifesting as an Ulcerated Gastric Cancer Complicated With Gastric Mucormycosis2021Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 6 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 1.2%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 2220242025: 112025

4 hospitals in Changsha for myasthenia gravis93 hospitals in China for myasthenia gravis

No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesThymus & thymectomyAntibodies & diagnosisStandard immunotherapy
Departments in papersNeurologyNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Wilson disease

肝豆状核变性(Wilson 病)

Led 7 of the 201 English-language PubMed papers on Wilson disease with an author in mainland China, 2021–2025: 3.5%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 0020222023: 1120232024: 1120242025: 222025

1 hospital in Changsha for Wilson disease28 hospitals in China for Wilson disease

No open trial on Wilson disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesGenetics (ATP7B)Diagnosis & copper testsChildren
Departments in papersOphthalmology / neuro-ophthalmologyGastroenterology / hepatologyNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 3 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 1.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 222025

3 hospitals in Changsha for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsNeurologyNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 5 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 2.7%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 2220232024: 0020242025: 002025

3 hospitals in Changsha for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 18 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 1.8%.

Papers led
18
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 3320212022: 1120222023: 7720232024: 5520242025: 222025

7 hospitals in Changsha for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led18
  1. The impact of psoriasis on idiopathic pulmonary fibrosis: a two-sample Mendelian randomization study.2025International journal of dermatology
  2. RTN3 regulates collagen biosynthesis and profibrotic macrophage differentiation to promote pulmonary fibrosis via interacting with CRTH2.2025Molecular medicine (Cambridge, Mass.)
  3. Molecular characterization of PANoptosis-related genes associated with immune infiltration and prognosis in idiopathic pulmonary fibrosis.2024International immunopharmacology
  4. ZCCHC8 p.P410A disrupts nucleocytoplasmic localization, promoting idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease.2024Molecular medicine (Cambridge, Mass.)
  5. The prognostic role of high-density lipoprotein cholesterol/C-reactive protein ratio in idiopathic pulmonary fibrosis.2024QJM : monthly journal of the Association of Physicians
  6. A nonsense mutation (c.382C>T) of PARN in a patient with idiopathic pulmonary fibrosis.2024QJM : monthly journal of the Association of Physicians
  7. Prevalence and prognostic value of malnutrition in patients with IPF using three scoring systems.2024Respiratory medicine
  8. A novel mutation (p.Y24N) in NHP2 leads to idiopathic pulmonary fibrosis and lung carcinoma chronic obstructive lung disease by disrupting the expression and nucleocytoplasmic localization of NHP2.2023Biochimica et biophysica acta. Molecular basis of disease
  9. CC Chemokines in Idiopathic Pulmonary Fibrosis: Pathogenic Role and Therapeutic Potential.2023Biomolecules
  10. Aspirin alleviates pulmonary fibrosis through PI3K/AKT/mTOR-mediated autophagy pathway.2023Experimental gerontology
  11. Analysis of necroptosis-related prognostic genes and immune infiltration in idiopathic pulmonary fibrosis.2023Frontiers in immunology
  12. Mitochondrial fission and bioenergetics mediate human lung fibroblast durotaxis.2023JCI insight
  13. Eupatilin inhibits pulmonary fibrosis by activating Sestrin2/PI3K/Akt/mTOR dependent autophagy pathway.2023Life sciences
  14. Integrative analysis reveals the recurrent genetic etiologies in idiopathic pulmonary fibrosis.2023QJM : monthly journal of the Association of Physicians
  15. DNA methylation in pulmonary fibrosis and lung cancer.2022Expert review of respiratory medicine
  16. Cofilin-1 promotes fibrocyte differentiation and contributes to pulmonary fibrosis.2021Biochemical and biophysical research communications
  17. Construction and validation of a bronchoalveolar lavage cell-associated gene signature for prognosis prediction in idiopathic pulmonary fibrosis.2021International immunopharmacology
  18. Associations Between Diabetes and Idiopathic Pulmonary Fibrosis: a Study-level Pooled Analysis of 26 Million People.2021The Journal of clinical endocrinology and metabolism
Chinese-language papers (not in the count)1
  1. Clinical evaluation on idiopathic pulmonary fibrosis.2021Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
Earlier papers (2016–2020)4
  1. MeCP2 epigenetically regulates alpha-smooth muscle actin in human lung fibroblasts.2020Journal of cellular biochemistry
  2. Glutaminolysis Epigenetically Regulates Antiapoptotic Gene Expression in Idiopathic Pulmonary Fibrosis Fibroblasts.2019American journal of respiratory cell and molecular biology
  3. Cigarette Smoke Extract Promotes Human Lung Myofibroblast Differentiation by the Induction of Endoplasmic Reticulum Stress.2019Respiration; international review of thoracic diseases
  4. Idiopathic Pulmonary Fibrosis: A Systemic Disease?2017Chinese medical journal
All its trials on ClinicalTrials.gov, any status11
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary FibrosisNot yet recruitingNCT07131150Study sitePhase 2Start 2025-08
  3. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09
  4. A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary FibrosisTerminatedNCT06360094Study sitePhase 2Start 2024-08
  5. A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT06335303Study sitePhase 2Start 2024-09
  6. Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary FibrosisTerminatedNCT06097260Study sitePhase 2Start 2023-11
  7. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05938920Study sitePhase 2Start 2023-06
  8. A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05321069Study sitePhase 3Start 2022-10
  9. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Study sitePhase 3Start 2021-03
  10. A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04594707Study sitePhase 3Start 2021-08
  11. Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT03955146Study sitePhase 3Start 2019-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病

Led 3 of the 45 English-language PubMed papers on lymphangioleiomyomatosis with an author in mainland China, 2021–2025: 6.7%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 112025

1 hospital in Changsha for lymphangioleiomyomatosis28 hospitals in China for lymphangioleiomyomatosis

No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

4 hospitals in Changsha for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

5 hospitals in Changsha for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Fbxl3 deletion mitigates myopathy in mdx mice through upregulation of myogenin.2025Biochemical and biophysical research communications

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

3 hospitals in Changsha for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 14 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 1.9%.

Papers led
14
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 3320222023: 5520232024: 1120242025: 222025

7 hospitals in Changsha for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Papers it led14
  1. Single-Cell RNA-Sequencing Analysis Provides Insights into IgA Nephropathy.2025Biomolecules
  2. The predictive value of suPAR for glomerular segmental sclerosis lesions in renal pathology.2025Renal failure
  3. Mechanistic study of celastrol-mediated inhibition of proinflammatory activation of macrophages in IgA nephropathy via down-regulating ECM1.2024International journal of biological sciences
  4. Identifying potential biomarkers for the diagnosis and treatment of IgA nephropathy based on bioinformatics analysis.2023BMC medical genomics
  5. EIF2α/ATF4 pathway enhances proliferation of mesangial cell via cyclin D1 during endoplasmic reticulum stress in IgA nephropathy.2023Clinical immunology (Orlando, Fla.)
  6. Network Pharmacology and Experimental Validation to Explore That Celastrol Targeting PTEN is the Potential Mechanism of Tripterygium wilfordii (Lév.) Hutch Against IgA Nephropathy.2023Drug design, development and therapy
  7. Clinical and pathological features of omicron variant of SARS-CoV-2-associated kidney injury.2023Journal of medical virology
  8. Changes in spectrum of biopsy-proven kidney diseases within decade: an analysis based on 10 199 cases from South China.2023Postgraduate medical journal
  9. Triptolide promotes autophagy to inhibit mesangial cell proliferation in IgA nephropathy via the CARD9/p38 MAPK pathway.2022Cell proliferation
  10. The influences of α-hemolytic Streptococcus on class switching and complement activation of human tonsillar cells in IgA nephropathy.2022Immunologic research
  11. Efficacy and indications of tonsillectomy in patients with IgA nephropathy: a retrospective study.2022PeerJ
  12. Immunofluorescence deposits in the mesangial area and glomerular capillary loops did not affect the prognosis of immunoglobulin a nephropathy except C1q:a single-center retrospective study.2021BMC nephrology
  13. Clinical implication of the circumferential crescents lesions in immunoglobulin A nephropathy: a single-center study of Han Chinese population.2021Human pathology
  14. Downregulation of miR‑214-3p attenuates mesangial hypercellularity by targeting PTEN‑mediated JNK/c-Jun signaling in IgA nephropathy.2021International journal of biological sciences
Chinese-language papers (not in the count)2
  1. Regulatory role of the mTOR signaling pathway in autophagy and mesangial proliferation in IgA nephropathy.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  2. Clinical outcomes for kidney transplantation in 81 adults with IgA nephropathy.2023Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
Earlier papers (2016–2020)20
  1. Coagulation parameters are associated with the prognosis of immunoglobulin a nephropathy: a retrospective study.2020BMC nephrology
  2. Immunostaining of galactose-deficient IgA1 by KM55 is not specific for immunoglobulin A nephropathy.2020Clinical immunology (Orlando, Fla.)
  3. microRNA-630 Regulates Underglycosylated IgA1 Production in the Tonsils by Targeting TLR4 in IgA Nephropathy.2020Frontiers in immunology
  4. Association analysis of DNA methyltransferases in IgA nephropathy.2020International immunopharmacology
  5. Dihydroartemisinin inhibits the proliferation of IgAN mesangial cells through the mTOR signaling pathway.2020International immunopharmacology
  6. The role of hypertriglyceridemia and treatment patterns in the progression of IgA nephropathy with a high proportion of global glomerulosclerosis.2020International urology and nephrology
  7. Retrospective Analysis of Clinical Outcomes in Patients with Immunoglobulin A Nephropathy and Persistent Hematuria Following Renin-Angiotensin System Blockade.2020Medical science monitor : international medical journal of experimental and clinical research
  8. Loss of the Golgi Matrix Protein 130 Cause Aberrant IgA1 Glycosylation in IgA Nephropathy.2019American journal of nephrology
  9. Serum immunoglobulin G provides early risk prediction in immunoglobulin A nephropathy.2019International immunopharmacology
  10. [Clinicopathological analysis for IgA nephropathy with isolated hematuria and/or mild proteinuria].2019Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  11. Impact of GADD34 on Apoptosis of Tonsillar Mononuclear Cells from IgA Nephropathy Patients by Regulating Eif2α Phosphorylation.2018Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  12. Prediction of ESRD in IgA Nephropathy Patients from an Asian Cohort: A Random Forest Model.2018Kidney & blood pressure research
  13. Rapamycin Enhances Repressed Autophagy and Attenuates Aggressive Progression in a Rat Model of IgA Nephropathy.2017American journal of nephrology
  14. Serum D-dimer is a potential predictor for thromboembolism complications in patients with renal biopsy.2017Scientific reports
  15. Tubular atrophy/interstitial fibrosis scores of Oxford classification combinded with proteinuria level at biopsy provides earlier risk prediction in lgA nephropathy.2017Scientific reports
  16. p53 induces miR199a-3p to suppress SOCS7 for STAT3 activation and renal fibrosis in UUO.2017Scientific reports
  17. Regulation of IgA Class Switch Recombination in Immunoglobulin A Nephropathy: Retinoic Acid Signaling and BATF.2016American journal of nephrology
  18. Potential diagnostic biomarkers for IgA nephropathy: a comparative study pre- and post-tonsillectomy.2016International urology and nephrology
  19. The efficacy of tonsillectomy on clinical remission and relapse in patients with IgA nephropathy: a randomized controlled trial.2016Renal failureRCT
  20. Efficacy of triptolide on the apoptosis of tonsillar mononuclear cells from patients with IgA nephropathy.2016Renal failure
All its trials on ClinicalTrials.gov, any status3
  1. Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f.Status unknownNCT02187900Lead sponsorPhase 3Start 2014-06
  2. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  3. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led no English-language PubMed papers on osteogenesis imperfecta in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

4 hospitals in Changsha for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07557446

    Age 12 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Changsha, Shanghai, Shenzhen, Suzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)RecruitingNCT07557446Study sitePhase 2Start 2026-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Changsha for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)2
  1. [Meta Analysis of Risks of Cardiocerebral Vascular Events in Patients with Primary Biliary Cholangitis].2019Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  2. Histone Posttranslational Modifications of CD4⁺ T Cell in Autoimmune Diseases.2016International journal of molecular sciences

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led 1 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Changsha for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Immune profiling of premalignant lesions in patients with Peutz-Jeghers syndrome.2025United European gastroenterology journal

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

中南大学湘雅二医院

Second Xiangya Hospital

长沙

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Second Xiangya Hospital of Central South University; Second Xiangya Hospital of Central South Unive; second Xiangya Hospital; Guilin Hospital of the Second Xiangya Hospital; Second Xiangya Hospital of Central-South University

Suggest a correctionDownload the data